COMPANY PROFILE

Outlook Therapeutics

A late clinical-stage biopharmaceutical company

Cranbury Township, United StatesFounded 2011Biotech & Life Sciences

Valuation $127M Market cap · 2026

Revenue $4.1M Latest reported FY

About Outlook Therapeutics

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing innovative ophthalmic treatments. The company is currently advancing ONS-5010, an investigational ophthalmic formulation of bevacizumab, through clinical trials for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases such as diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). ONS-5010 is designed to be administered as an intravitreal injection, directly into the eye, to inhibit vascular endothelial growth factor (VEGF) and associated angiogenic activity, which are key factors in these retinal conditions. If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab for these indications.

The company operates in the biopharmaceutical market, primarily serving patients with retinal diseases and collaborating with healthcare providers and research institutions. Outlook Therapeutics' business model revolves around the development, clinical testing, and eventual commercialization of its proprietary ophthalmic formulations. Revenue generation is expected to come from the sale of FDA-approved treatments and potential partnerships or licensing agreements with other pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2011
Headquarters: Cranbury Township, United States
Listing: IPO 2016
Employees: 65
Open positions: 10
Dealroom signal: 58.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	Apr 2026	$5M	—	Undisclosed	↗
POST IPO DEBTDebt	Mar 2026	$18M	—	Altasciences	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026	$4.1M	+191.6%	−$107M	-2585.9%
2025	$1.4M	—	−$107M	-7540.8%
2024	$0	—	−$73M	—
2023	$0	—	−$53M	—
2022	$0	-100%	−$63M	—
2021	$8.1M	0%	−$52M	-635.6%
2020	$8.1M	—	−$36M	-445.8%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Outlook Therapeutics website traffic

Latest recorded traffic for Outlook Therapeutics is 28K monthly website visits, up 133.3% over the last three months. Outlook Therapeutics's team grew 25% over the past year.

Latest monthly visits28K 3-month web change+133.3% 1-year team growth+25%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

IT Manager (remote)Cranbury, Cranbury Township, Middlesex County, New Jersey, United States · Backend Development · Sep 4, 2026 Head of Business Engagement for Strategic Accounts, GPO and ContractingMission, Kansas, United States, Northern America, Americas · Accounting · Sep 1, 2026 Access & Reimbursement Manager (ARM) - NortheastBoston, MA · Accounting · Sep 1, 2026 Access & Reimbursement Manager (ARM) - WestDenver, CO · Accounting · Aug 31, 2026 National Sales Director - WestDallas, TX · Sales · Aug 31, 2026 Access & Reimbursement Manager (ARM) - Mid-Atlantic / DMVPhiladelphia, PA · CSM & Support · Aug 30, 2026 Head of Business Engagement for Strategic Accounts, GPO and ContractingCranbury, Cranbury Township, Middlesex County, New Jersey, United States · Accounting · Aug 30, 2026 Director – Trade & DistributionCranbury, Cranbury Township, Middlesex County, New Jersey, United States · Marketing & Communication · Aug 28, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NGNest GenomicsMaking genetic testing mainstream and integrated into patient care is difficult, Â Nest makes it easy	New York City, United States	Operational	17	$11M	$34M
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
OMOmicsChartPatient-centric cancer data and analytics platform for translational cancer biologists	Cardiff, United Kingdom	Operational
LILinusBioPatient-centric precision exposome medicine, uncovering biomarkers and targets for diseases with historically limited molecular endpoints, spanning CNS, gastroenterology, renal disease, and oncology	North Brunswick Township, United States	Operational
CHChemotargetsChemotargets is a computationally-oriented biotech company	Barcelona, Spain	Operational
KPKantum PharmaTargeted therapies to prevent and treat damaging inflammation by the innate immune system	Concord, United States	Operational
UIUnited ImmunityThis company focuses on developing nanotechnology-based solutions to improve immunity and fight cancer and infectious diseases	Osaka, Japan	Operational
BEBetterOmicsAn AI cloud for omics data analysis, providing a centralized platform for reproducible validation, data traceability, and AI-powered insights, and featuring secure clinical-grade security and GxP compliance	Menlo Park, United States	Operational